REVB: Revelation Bio Price to Sales
Revelation Biosciences focuses on developing Gemini to combat lung and kidney pathologies, leveraging robust patent protection. The price-to-sales ratio dynamics, with the metric fixed at , clearly demonstrate market expectations. However, high risks of test failure and competition from industry behemoths create threats, while the need to rapidly capture the niche compels the company to accelerate its clinical cycles.
Analytical breakdowns for Revelation Bio (REVB)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- issuer credit burden and liquidity indicators:
Debt to Equity Revelation Biosciences|REVB - Long-Term Debt to Capital|Current Liabilities to Capital Revelation Biosciences Corp|REVB - Company Debts|Debt to Book Capitalization Ratio Revelation Bio|REVB - Company Long-Term Debts|Company Short-Term Debts Revelation Biosciences|Intermediate Liquidity Ratio revbiosciences.com
- earnings and valuation multiples information:
REVB - Net Profit|Company Profit Forecast Revelation Biosciences|REVB - Price to Earnings Ratio|Projected Price to Earnings Ratio Revelation Biosciences Inc|REVB - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Revelation Bio|REVB - Operating profit before deduction of amortization|Earnings per share for the trailing year Revelation Biosciences|REVB - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months revbiosciences.com|REVB - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Revelation Biosciences
- issuer revenue and sales details:
Fundamental company analysis:revbiosciences.com REVB
The P/S ratio determines the market value of a business relative to its annual revenue, allowing an investor to assess the premium paid per unit of generated income. By analyzing the P/S ratio of Revelation Biosciences (REVB), one can compare the capitalization of Revelation Biosciences (REVB) with the efficiency of its scientific developments in immunology, where a lack of bureaucracy and a focus on talent drive future sales growth.
Competing companies
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio PTGX (Protagonist Corp)|IMVT: P/S Multiple|Price to Sales kiniksa.com (KNSA)|Market Cap to Revenue GRFS|Price-to-Revenue Ratio ADPT|P/S Multiple CLDX|AUPH - Price to Sales|Price-to-Revenue Ratio BioCryst BCRX|veratx.com - Price-to-Revenue Ratio|Dianthus Therapeutics, Inc. - P/S Multiple|PHVS - P/S Multiple|ABCL (AbCellera Biologics Inc) - Market Cap to Revenue|TRML: Market Cap to Sales Volume|PGEN (Precigen, Inc.) - P/S Multiple|pharming.com (PHAR) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Nektar Therapeutics Inc. (NKTR)|UPB - Price to Sales|Price-to-Revenue Ratio Zenas Biopharma, Inc. ZBIO|IMNM: Market Cap to Revenue Ratio|GOSS: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio KALV (kalvista.com)|SEPN: P/S Multiple|PVLA (Pieris Pharma) - Price-to-Revenue Ratio|SVRA (Savara Corp) - P/S Multiple|Rigel Corp (RIGL) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio AnaptysBio, Inc. (ANAB)|ATXS - Price to Sales|Price-to-Revenue Ratio enGene ENGN|Price-to-Revenue Coefficient RAPT Therapeutics Inc. (RAPT)|Aerovate - P/S Multiple|Aclaris Therapeutics, Inc (ACRS) - Market Cap to Revenue|KYTX: P/S Multiple|TLSA - Price-to-Revenue Coefficient|CABA (Cabaletta Bio) - P/S Multiple|Price to Sales Ventyx Biosciences Inc. VTYX|Price-to-Revenue Ratio Theratechnologies Inc (THTX)|Avalo Therapeutics Inc - Market Cap to Revenue Ratio|P/S Multiple ELDN (Eledon Pharmaceuticals)|AGEN - Market Cap to Revenue|Climb Bio - P/S Multiple|Price to Sales Zura Bio Ltd|aTyr (ATYR) - Price-to-Revenue Ratio|ADAG - Price-to-Revenue Coefficient|Price-to-Revenue Ratio ImageneBio|STTK: Market Capitalization-to-Revenue Ratio|P/S Multiple EQ|CNTB - Price to Sales|Immunic - Market Cap to Revenue|Atara Biotherapeutics, Inc. - Price-to-Revenue Ratio|InflaRx GmbH - P/S Multiple|XFOR: Price-to-Revenue Ratio|adicetbio.com (ACET) - Price-to-Revenue Ratio|Price-to-Sales Ratio CELU (Celularity)|INMB (INmune Bio Corp) - P/S Multiple|BRNS: Market Capitalization-to-Revenue Ratio|P/S Multiple KZR|P/S Multiple sabbiotherapeutics.com (SABS)|Price-to-Revenue Ratio Akari Therapeutics Plc AKTX|Market Capitalization-to-Revenue Ratio ENLV|QTTB - Price-to-Revenue Ratio|GeoVax Corp (GOVX) - Market Cap to Revenue|EDSA: P/S Multiple|ibioinc.com (IBIO) - P/S Multiple|Market Cap to Revenue CARM|XTLB: Market Capitalization-to-Revenue Ratio|P/S Multiple BOLT|Price-to-Revenue Coefficient hcwbiologics.com|Price-to-Revenue Ratio Aptevo Therapeutics Inc. APVO|AIM - Market Cap to Revenue|ADTX - Price-to-Revenue Ratio|GRI Bio Inc (GRI) - Market Cap to Revenue|XRTX (XORTX) - Market Cap to Revenue|Vyome Therapeutics (HIND) - P/S Multiple|Price-to-Revenue Ratio Indaptus Therapeutics|Market Cap to Revenue Ratio SCNI (scinai.com)|P/S Multiple CALI|AFMD - Price to Sales|Price-to-Revenue Ratio Allakos ALLK|Market Capitalization-to-Revenue Ratio HOOK|IGM Bio - P/S Multiple|Price to Sales iteostherapeutics.com|OCEA (Ocean Biomedical) - Market Cap to Revenue|TCBP (TC BioPharm (Holdings) Plc) - Price-to-Revenue Ratio|THRD (Third Harmonic Bio, Inc) - P/S Multiple
